Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general population, representing a major public health concern that implies a high economic burden for the health system. Levosimendan in HF patients is usually used for its inotropic and vasodilator effects that act without myocardial oxygen consumption, differently from other inotropic drugs. The symptoms and hemodynamic profile improve together with the myocardial function, and this can be demonstrated by an echocardiographic examination. Currently, the available data about the effects of levosimendan assessed by echocardiography are still lacking. This review discusses the role of echocardiography in the evaluation of therapeutic effects of levosim...
Eugene Pashkovetsky, Chhaya Aggarwal Gupta, Wilbert S AronowDivision of Cardiology, Department of Me...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general po...
Abstract BACKGROUND: Levosimendan (L) is used in clinical practice for the treatment of severe hear...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Background: Levosimendan is a calcium sensitizer and K+-ATP channel opener with inotropic and vasodi...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Heart failure is a very common clinical pathology. The treatment of heart failure is expensive; ther...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Levosimendan is a new inotropic agent licensed in 10 European countries (Simdax, Orion Pharma, Finla...
Aims The long-term clinical effects of Levosimendan in patients (pts) with heart failure and reduce...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
Eugene Pashkovetsky, Chhaya Aggarwal Gupta, Wilbert S AronowDivision of Cardiology, Department of Me...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general po...
Abstract BACKGROUND: Levosimendan (L) is used in clinical practice for the treatment of severe hear...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Background: Levosimendan is a calcium sensitizer and K+-ATP channel opener with inotropic and vasodi...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...
Heart failure is a very common clinical pathology. The treatment of heart failure is expensive; ther...
International audienceWHAT IS KNOWN AND OBJECTIVE: Positive inotropic agents are frequently used in ...
Levosimendan is a new inotropic agent licensed in 10 European countries (Simdax, Orion Pharma, Finla...
Aims The long-term clinical effects of Levosimendan in patients (pts) with heart failure and reduce...
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe...
Eugene Pashkovetsky, Chhaya Aggarwal Gupta, Wilbert S AronowDivision of Cardiology, Department of Me...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompen...